| 1 |
35045964 | Correction: SAR405838: A Novel and Potent Inhibitor of the MDM2:p53 Axis for the Treatment of Dedifferentiated Liposarcoma. | 2022 Jan 15 |
1 |
| 2 |
27550999 | Therapeutic Inhibition of the MDM2-p53 Interaction Prevents Recurrence of Adenoid Cystic Carcinomas. | 2017 Feb 15 |
1 |
| 3 |
28324749 | A phase I study of SAR405838, a novel human double minute 2 (HDM2) antagonist, in patients with solid tumours. | 2017 May |
1 |
| 4 |
28498808 | Restoration of p53 using the novel MDM2-p53 antagonist APG115 suppresses dedifferentiated papillary thyroid cancer cells. | 2017 Jun 27 |
1 |
| 5 |
26475335 | SAR405838: A Novel and Potent Inhibitor of the MDM2:p53 Axis for the Treatment of Dedifferentiated Liposarcoma. | 2016 Mar 1 |
4 |
| 6 |
27576846 | TP53 mutations emerge with HDM2 inhibitor SAR405838 treatment in de-differentiated liposarcoma. | 2016 Aug 31 |
1 |
| 7 |
27764791 | Novel MDM2 inhibitor SAR405838 (MI-773) induces p53-mediated apoptosis in neuroblastoma. | 2016 Dec 13 |
5 |
| 8 |
27765850 | Reactivation of p53 by MDM2 Inhibitor MI-77301 for the Treatment of Endocrine-Resistant Breast Cancer. | 2016 Dec |
1 |
| 9 |
25754349 | Elucidation of Acquired Resistance to Bcl-2 and MDM2 Inhibitors in Acute Leukemia In Vitro and In Vivo. | 2015 Jun 1 |
2 |
| 10 |
26070072 | Significant Differences in the Development of Acquired Resistance to the MDM2 Inhibitor SAR405838 between In Vitro and In Vivo Drug Treatment. | 2015 |
2 |
| 11 |
25145672 | SAR405838: an optimized inhibitor of MDM2-p53 interaction that induces complete and durable tumor regression. | 2014 Oct 15 |
1 |